Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the company’s stock with a ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.